Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street ...

Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...

US pharmaceutical giant Pfizer Inc returned to profit in the fourth quarter from a loss in the same period of the previous ...

Spotify (NYSE: SPOT) stock surged 8.3% after the music streaming company reported fourth-quarter 2024 results that exceeded ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

These sensational income stocks -- sporting an average yield of 6.15% -- can fatten investors' pocketbooks for a long time to ...